|
gptkbp:instanceOf
|
gptkb:drug
opioid
|
|
gptkbp:administeredBy
|
hospitals
emergency medicine
ambulance services
healthcare professionals
bystanders (in some regions)
|
|
gptkbp:antidote
|
opioid toxicity
|
|
gptkbp:approvedBy
|
gptkb:FDA
1971
|
|
gptkbp:ATCCode
|
V03AB15
|
|
gptkbp:brand
|
gptkb:Narcan
gptkb:Evzio
|
|
gptkbp:CASNumber
|
465-65-6
|
|
gptkbp:chemicalClass
|
opioid
|
|
gptkbp:contraindication
|
hypersensitivity to naloxone
|
|
gptkbp:developedBy
|
gptkb:Sankyo
|
|
gptkbp:discoveredIn
|
1960
|
|
gptkbp:eliminationHalfLife
|
30–81 minutes
|
|
gptkbp:enemyOf
|
gptkb:delta-opioid_receptor
gptkb:kappa-opioid_receptor
gptkb:mu-opioid_receptor
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
injectable solution
nasal spray
|
|
gptkbp:hasMolecularFormula
|
C19H21NO4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Naloxone
|
|
gptkbp:KEGGID
|
D08367
|
|
gptkbp:legalStatus
|
prescription only (varies by country)
|
|
gptkbp:mechanismOfAction
|
opioid
|
|
gptkbp:MedlinePlusID
|
a612022
|
|
gptkbp:MeSH_ID
|
D009285
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notEffectiveAgainst
|
non-opioid drug overdose
|
|
gptkbp:OTC
|
yes (in some countries)
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
5284596
DB01183
4447621
CHEMBL1519
|
|
gptkbp:routeOfAdministration
|
intramuscular
subcutaneous
intravenous
intranasal
|
|
gptkbp:sideEffect
|
nausea
vomiting
hypertension
sweating
tachycardia
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:synonym
|
gptkb:N-allylnoroxymorphone
|
|
gptkbp:UNII
|
KBQ1YD99ER
|
|
gptkbp:usedFor
|
opioid overdose
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Antidotes
gptkb:Antidote
gptkb:Opiate
|
|
gptkbp:bfsLayer
|
5
|